Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Assets: 2012-2024

Historic Other Non-Current Assets for Agios Pharmaceuticals (AGIO) over the last 12 years, with Dec 2024 value amounting to $4.7 million.

  • Agios Pharmaceuticals' Other Non-Current Assets fell 3.11% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 3.11%. This contributed to the annual value of $4.7 million for FY2024, which is 16.44% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $4.7 million for FY2024, which was up 16.44% from $4.1 million recorded in FY2023.
  • In the past 5 years, Agios Pharmaceuticals' Other Non-Current Assets ranged from a high of $47.9 million in FY2020 and a low of $2.9 million during FY2021.
  • For the 3-year period, Agios Pharmaceuticals' Other Non-Current Assets averaged around $4.2 million, with its median value being $4.1 million (2023).
  • In the last 5 years, Agios Pharmaceuticals' Other Non-Current Assets slumped by 93.94% in 2021 and then skyrocketed by 36.41% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $47.9 million in 2020, then tumbled by 93.94% to $2.9 million in 2021, then surged by 36.41% to $4.0 million in 2022, then increased by 2.55% to $4.1 million in 2023, then climbed by 16.44% to $4.7 million in 2024.